Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 70 full-time employees. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Follow-Up Questions
Who is the CEO of Lineage Cell Therapeutics Inc?
Mr. Brian Culley is the Chief Executive Officer of Lineage Cell Therapeutics Inc, joining the firm since 2018.
What is the price performance of LCTX stock?
The current price of LCTX is $1.98, it has increased 1.02% in the last trading day.
What are the primary business themes or industries for Lineage Cell Therapeutics Inc?
Lineage Cell Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Lineage Cell Therapeutics Inc market cap?
Lineage Cell Therapeutics Inc's current market cap is $452.1M
Is Lineage Cell Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Lineage Cell Therapeutics Inc, including 3 strong buy, 8 buy, 2 hold, 0 sell, and 3 strong sell
